FDA Regulatory Clarity On Peptides is a Turning Point for Millions of Americans

A joint statement from Max Marchione, Founder & CEO, and Dr. Anant Vinjamoori, Chief Longevity Officer

At Superpower, we believe every American deserves a responsible pathway to innovations that can extend and enhance healthy life.

The FDA's decision to bring regulatory clarity to peptide therapy is overdue and welcome, and marks a turning point for one of the most consequential emerging categories in medicine.

Patients exploring any new area of medicine need clear information, thoughtful guidance, and care they can trust. The FDA's effort to clarify the regulatory status of several peptides is an important step toward delivering these treatments through trusted channels and vetted clinicians. As the framework for peptide therapy takes shape, we are committed to meeting it with the patient safety, transparency, and clinical rigor Americans deserve.

The human body naturally produces thousands of peptides, and GLP-1s, a single family among them, have already reshaped metabolic health for millions of Americans. As research continues, new variants will emerge with applications across recovery, metabolic health, and longevity. These therapies share a need for the same foundation: clinical oversight, honest communication about what is known and what is not, and the infrastructure to deliver them safely at scale.

We believe in a comprehensive standard of longevity care — one that combines biomarker testing, clinical guidance, and responsible access to new therapies as they emerge.

We will continue to set a standard in this space that Americans can trust as they invest in their long-term health.